Tag: GlobeNewswire

SAN JOSE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — Astera Labs, Inc. (Nasdaq: ALAB), a leader in semiconductor-based connectivity solutions for rack-scale AI infrastructure, today announced that it will release its financial results for the third quarter 2026 after the close of market on Tuesday, Nov. 3, 2026. Astera Labs will host a corresponding conference call at 1:30 p.m. Pacific Time, 4:30 p.m. Eastern Time.

Conference Call Details
Date:	Nov. 3, 2026
Time:	1:30 pm PT / 4:30 pm ET
Hosts:	Jitendra Mohan, Chief Executive Officer Sanjay Gajendra, President and Chief Operating Officer Des Lynch, Chief Financial Officer
Dial-in:	1 (833) 461-5787 Conference ID: 751 181 378
Webcast:	https://ir.asteralabs.com

About Astera Labs
Astera Labs (NASDAQ: ALAB) provides rack-scale AI infrastructure through purpose-built connectivity solutions. By collaborating with hyperscalers and ecosystem partners, Astera Labs enables organizations to unlock the full potential of modern AI. Astera Labs’ Intelligent Connectivity Platform integrates CXL^®, Ethernet, NVLink Fusion, PCIe^®, and UALink™ semiconductor-based technologies with the company’s COSMOS software suite to unify diverse components into cohesive, flexible systems that deliver end-to-end scale-up, and scale-out connectivity. The company’s custom connectivity solutions business complements its standards-based portfolio, enabling customers to deploy tailored architectures to meet their unique infrastructure requirements. Discover more at www.asteralabs.com.

© Astera Labs, Inc.  Astera Labs, and its stylized logo, are trademarks of Astera Labs, Inc. or its affiliates. Other names and brands may be claimed as the property of others.

Investor Contact:
Leslie Green
Leslie.green@asteralabs.com

• Strategic Milestone: Official opening of the Robotics Training, Data and Experience Center in Singapore to support humanoid training, workflow testing, and customer demonstrations.
• Tapping a US$68.1 Billion Market: Capitalizing on the global service robotics market—estimated at US$68.1 billion in 2026 and projected to reach US$107.8 billion by 2030—alongside the US$5.41 billion humanoid robot sector.
• Commercial Pathway: Designed to evaluate Robotics-as-a-Service (“RaaS”), robot leasing, and managed services as potential recurring revenue streams supporting the Company’s 2030 vision.

SINGAPORE, Oct. 06, 2026 (GLOBE NEWSWIRE) — YYForce Inc. (NASDAQ: YFOR) (“YYForce” or the “Company”), a technology-enabled workforce solutions and integrated facility management company, today announced the official opening of its Robotics Training, Data and Experience Center (the “Center”) in Singapore. The facility supports humanoid robot training, operational data collection, workflow testing, and customer demonstrations across hospitality, cleaning, security, delivery, and facility management applications.

The Center is designed to help YYForce translate robotics technologies into practical customer solutions, drawing on its existing workforce and facility management operations. It also supports the Company’s evaluation of Robotics-as-a-Service (“RaaS”), robot leasing, and managed robotic services as potential sources of recurring revenue.

Capitalizing on the US$68.1 Billion Commercial Robotics Opportunity

YYForce believes Singapore offers an attractive environment for robotics adoption as service operators seek to improve productivity, manage manpower constraints, and maintain consistent service quality. In May 2026, the Infocomm Media Development Authority (IMDA), JTC Corporation (JTC), and the Singapore Institute of Technology (SIT) announced a physical AI testbed at Punggol Digital District, planned for later in 2026, with applications including delivery, cleaning, and security patrolling. This initiative provides wider market context; YYForce is not announcing participation in that programme.

Globally, Grand View Research estimates the service robotics market at US$68.1 billion in 2026 and projects it to reach US$107.8 billion by 2030. Separately, MarketsandMarkets estimates the global humanoid robot market at US$5.41 billion in 2026 and projects US$50.27 billion by 2035. These forecasts cover different, potentially overlapping categories and are not additive. They provide industry context, rather than estimates of Singapore demand or YYForce’s addressable revenue.

For the 2026–2031 period, YYForce sees opportunities to evaluate specialized service robots for defined commercial tasks while developing humanoid applications through training and testing. The Company intends to assess deployment opportunities based on task performance, safety, reliability, required human supervision, and customer economics.

Humanoid Training and Operational Data Collection

The Center includes simulated service environments for training and evaluating humanoid robots in selected hotel housekeeping, restroom cleaning, banqueting, and hospitality support workflows. It also supports testing of collaboration among human workers, humanoid robots, and specialized service robots.

Through repeated training and testing, YYForce is collecting operational data relating to navigation, movement, object interaction, task execution, and environmental conditions. Though training and demonstration activities do not establish that humanoid robots can yet perform complete housekeeping or restroom-cleaning duties autonomously, these activities are intended to help evaluate performance and adapt workflows to specific service environments.

Service Robotics and Integrated Security Demonstrations

The Center showcases indoor and outdoor commercial cleaning robots, food and item delivery robots, autonomous security and surveillance robots, swimming pool cleaning robots, humanoid service robots, and other specialized systems. Customers and potential partners can evaluate how these technologies may fit within their operations.

A live Security Command Center, as part of the Center, demonstrates the integration of robotic patrol capabilities, surveillance systems, sensors, cameras, and centralized monitoring. This environment enables YYForce to evaluate how robotic and monitoring technologies can complement security personnel and broader facility management services.

Building a Path to Recurring Robotics Revenue

The Center anticipates to support a structured commercialization pathway: training and data collection, workflow testing, customer demonstrations, proofs of concept, and, where viable, commercial deployment. Potential applications include hotels, commercial buildings, residential developments, retail premises, warehouses, and other service environments.

YYForce is evaluating commercial arrangements that could combine robot access with deployment support, maintenance, monitoring, and human service capabilities. Potential RaaS and leasing models would allow customers to access robotics through recurring arrangements without necessarily purchasing hardware outright. Integrated service contracts could combine people and robots within a single service-delivery model.

The Company believes its existing operating experience can help identify suitable tasks, evaluate customer requirements, and coordinate human-robot workflows. Commercial viability will depend on productivity gains, service quality, deployment and integration costs, maintenance requirements, and the level of human intervention needed.

At this stage, the Company has not yet announced material revenue attributable to these proposed robotics business models. The Center’s opening does not represent an announcement of material robotics orders or contracted recurring revenue. Future commercialization remains subject to customer adoption, technology performance, deployment economics, and other factors.

Supporting the YYForce 2030 Vision

The Center anticipates to support YYForce’s 2030 vision of becoming a Future Workforce Solutions Provider by integrating human talent, AI-enabled technologies, humanoid robots, and specialized autonomous robots. Human workers would continue to perform activities requiring judgment, communication, and flexibility, while suitable robotic systems could support repetitive, physically demanding, and monitoring-intensive tasks.

Chief Executive Officer Commentary

Mike Fu, Chief Executive Officer of YYForce, commented:

“Our objective is to help customers put robotics to work in everyday service operations. Our existing workforce and facility management experience gives us direct insight into the tasks customers need completed and the standards they expect.”

“This center provides a dedicated working environment to train humanoid robots, collect operational data, and evaluate service robots prior to customer deployment. We see clear opportunities to develop recurring service relationships through leasing and managed robotics, while rigorously testing each application against performance and cost requirements.”

“Our 2030 vision brings people, AI, and robotics together to elevate how services are delivered. We will pursue that vision through practical applications and disciplined commercial execution — Forging Forward Together.”

About YYForce Inc.

YYForce Inc. (NASDAQ: YFOR) is a technology-enabled workforce solutions and integrated facility management company focused on how businesses access, manage, and deploy workforce and facility services. The Company is developing an ecosystem combining on-demand workforce technology, integrated facility management, artificial intelligence, automation, humanoid robotics, and specialized service robots to support productivity, operational flexibility, and scalability.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the Company’s robotics strategy, training and data collection activities, potential customer applications, RaaS and leasing models, managed services, recurring revenue opportunities, and YYForce’s 2030 vision, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company bases these forward-looking statements on its expectations and projections about future events, which the Company derives from the information currently available to it. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. . Third-party market forecasts are estimates and may not be realized.

Forward-looking statements involve inherent risks and uncertainties, and the forward-looking events discussed in this press release may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about the Company and a number of factors. These factors include, but are not limited to, customer adoption, technology reliability and safety, integration requirements, data governance, financing and hardware availability, maintenance costs, and deployment economics. There can be no assurance that the Company’s robotics initiatives or proposed commercial models will be successfully implemented or generate material revenue. For a more detailed discussion of risk factors, please refer to the Company’s filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Company’s most recent annual report on Form 20-F, as amended. Readers should also consider the risks described in the Company’s filings with the U.S. Securities and Exchange Commission. YYForce undertakes no obligation to update these statements except as required by applicable law.

Investor Contact
Jason Zhi Yong Phua, Chief Financial Officer
YYForce Inc.
enquiries@yyforce.ai

Investor Relations Contact
Piacente Financial Communications
yfor@thepiacentegroup.com

Market Sources
[1] JTC, Singapore Government and Eight Industry Leaders to Research, Test and Deploy Physical AI in Punggol Digital District, May 20, 2026.
[2] Grand View Research, Service Robotics Market 2024–2030, public report summary accessed October 2, 2026.
[3] MarketsandMarkets, Humanoid Robot Market — Global Forecast to 2035, July 2026.

HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) — Sysco Corporation (NYSE:SYY) (“Sysco” or the “Company”) today announced that Sysco and Sysco Holdings Corporation, a Delaware corporation and wholly-owned subsidiary of Sysco (“Sysco Holdings” and, together with Sysco, the “Issuers”), have closed public offerings (collectively, the “Offerings”) of $14.65 billion in aggregate principal amount of notes and €1.0 billion in aggregate principal amount of notes consisting of the following securities:

• $1.75 billion in aggregate principal amount of 5.450% Senior Notes due 2029;
• $2.0 billion in aggregate principal amount of 5.600% Senior Notes due 2031;
• $1.5 billion in aggregate principal amount of 5.800% Senior Notes due 2033;
• $2.0 billion in aggregate principal amount of 5.950% Senior Notes due 2036;
• $1.0 billion in aggregate principal amount of 6.400% Senior Notes due 2046;
• $1.75 billion in aggregate principal amount of 6.500% Senior Notes due 2056;
• $750 million in aggregate principal amount of 6.600% Senior Notes due 2066 (collectively, the “Senior Notes”);
• $1.5 billion in aggregate principal amount of 7.100% Series A Junior Subordinated Notes due 2056;
• $1.0 billion in aggregate principal amount of 7.250% Series B Junior Subordinated Notes due 2056;
• $1.4 billion in aggregate principal amount of 7.350% Series C Junior Subordinated Notes due 2056 (collectively, the “USD Junior Subordinated Notes”); and
• €1.0 billion in aggregate principal amount of 6.000% Junior Subordinated Notes due 2056 (the “Euro Junior Subordinated Notes” and, together with the Senior Notes and the USD Junior Subordinated Notes, the “Notes”).

The Issuers estimate that they will receive approximately $10.64 billion from the offering of the Senior Notes, approximately $3.8 billion from the offering of the USD Junior Subordinated Notes and approximately €0.99 billion from the offering of the Euro Junior Subordinated Notes, in each case after deducting underwriting discounts and estimated offering expenses payable by them. The Issuers intend to use the net proceeds from the Offerings to pay a portion of the cash consideration for the pending acquisition of Jetro Restaurant Depot, and all other fees, costs and expenses related thereto or, if the acquisition is not consummated, to pay for the special mandatory redemption of the Notes (other than the 5.950% Senior Notes due 2036) pursuant to their terms.

The Offerings were made by means of applicable prospectus supplements under the Issuers’ shelf registration statement on Form S-3ASR, as filed with the Securities and Exchange Commission (the “SEC”).

Goldman Sachs & Co. LLC, TD Securities (USA) LLC, BofA Securities, Inc., J.P. Morgan Securities LLC, Wells Fargo Securities, LLC, BNP Paribas Securities Corp., PNC Capital Markets LLC, Truist Securities, Inc. and U.S. Bancorp Investments, Inc. acted as joint book-running managers for the offerings of the Senior Notes and the USD Junior Subordinated Notes. Goldman Sachs & Co. LLC, TD Global Finance unlimited company, Merrill Lynch International, J.P. Morgan Securities plc, Wells Fargo Securities International Limited, PNC Capital Markets LLC and U.S. Bancorp Investments, Inc. acted as joint book-running managers for the offering of the Euro Junior Subordinated Notes.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the Notes, nor does it constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale is unlawful. The Offerings were made in the U.S. only by means of prospectus supplements relating to the Offerings and the accompanying prospectus.

Copies of the final prospectus supplements for the Offerings and the accompanying prospectus may be obtained free of charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the final prospectus supplements for the Senior Notes and USD Junior Subordinated Notes may be obtained by calling Goldman Sachs & Co. LLC toll free at 1-866-471-2526, TD Securities (USA) LLC toll free at 1-855-495-9846, BofA Securities, Inc. toll free at 1-800-294-1322, J.P. Morgan Securities LLC collect at 212-834-4533 or Wells Fargo Securities, LLC toll free at 1-800-645-3751 (option #5); copies of the final prospectus supplement for the Euro Junior Subordinated Notes may be obtained by calling Goldman Sachs & Co. LLC toll free at 1-866-471-2526, TD Global Finance unlimited company at +44 20 7628-2262, J.P. Morgan Securities plc (for non-U.S. investors) at +44-20 7134-2468, Merrill Lynch International, toll-free at 1-800-294-1322 or J.P. Morgan Securities LLC (for U.S. investors) at +1-212 834-4533.

About Sysco

Sysco is the global leader in selling, marketing and distributing food and related products to customers who prepare meals away from home. This includes restaurants, healthcare and educational facilities, lodging establishments, entertainment venues, and more. Sysco operates 333 distribution centers, in 10 countries, with 75,000 colleagues serving approximately 670,000 customer locations. The company generated sales of more than $84 billion in fiscal year 2026 that ended June 27, 2026.

As the world’s largest food-away-from-home distributor, Sysco offers customized supply chain solutions, bespoke specialty product offerings, and culinary support to drive customers to innovate and optimize their operations. We act as a trusted business partner to our customers, helping them grow through our industry-leading portfolio that includes fresh produce, premium proteins, specialty products, sustainably focused items, equipment and supplies, and innovative culinary solutions.

SYY-INVESTORS

Forward-Looking Statements

Statements made in this press release include statements that are forward-looking or that express management’s beliefs, expectations or hopes and are forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements include, among other things, statements regarding the terms, timing and completion of the Offerings and our anticipated use of the proceeds thereof, statements about our future financial performance and results, business strategy, plans, goals and objectives, and other statements that are not historical facts, including expectations regarding our future growth, including growth in sales and earnings per share, expectations regarding cost savings associated with AI, as well as statements about the expected timing and completion of the proposed transaction with Jetro Restaurant Depot and the anticipated benefits of such proposed transaction.

Such forward-looking statements reflect the views of management at the time such statements are made and are subject to a number of risks, uncertainties, estimates, and assumptions, including those outside of Sysco’s control. Risks and uncertainties include without limitation: the impact of geopolitical, economic and market conditions and developments, including changes in global trade policies and tariffs and foreign conflicts; risks related to our business initiatives; periods of significant or prolonged inflation or deflation and their impact on our product costs, volume, foot traffic, and profitability generally; risks related to our efforts to implement our transformation initiatives and meet our other long-term strategic objectives; risks of interruption of supplies and increase in product costs; risks related to changes in consumer eating habits; and impact of natural disasters or adverse weather conditions, public health crises, adverse publicity or lack of confidence in our products, and product liability claims as well as risks and uncertainties associated with our proposed transaction with Jetro Restaurant Depot, including but not limited to, the occurrence of any event, change or other circumstances that could give rise to the right of either or both parties to terminate the merger agreement; the risk that regulatory approvals may not be obtained or other closing conditions may not be satisfied in a timely manner or at all, as well as the risk that regulatory approvals are obtained subject to conditions that are not anticipated; the risk of other delays in closing the transaction; the possibility that any of the anticipated benefits and projected synergies of the transaction will not be realized or will not be realized within the expected time period; and the risk that the proposed transaction and its announcement could have an adverse effect on the market price of the common stock of Sysco. Should one or more of these risks or uncertainties materialize, or underlying assumptions prove incorrect, actual results may vary materially from those indicated in our forward-looking statements. Therefore, you should not place undue reliance on any of the forward-looking statements contained herein. For more information on these risks and other concerning factors that could cause actual results to differ from those expressed or forecasted, see our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and other filings with the SEC. We do not undertake to update our forward-looking statements, except as required by applicable law.

For more information contact:
Kevin Kim	Cassandra Mauel
Investor Contact	Media Contact
kevin.kim@sysco.com	cassandra.mauel@sysco.com
T 281-584-1219	T 281-584-1390

DURANGO, Colo., Oct. 06, 2026 (GLOBE NEWSWIRE) — Rocky Mountain Chocolate Factory, Inc. (Nasdaq: RMCF) (the “Company” or “RMCF”), America’s Chocolatier^® since 1981, today announced it has signed a $6.6 million sale-leaseback agreement with American Heritage Legacies, LLC, involving its Durango, Colorado property. American Heritage Legacies, LLC, is a local company controlled by the family of Allen Harper, the Company’s Interim Chief Executive Officer. As such, the sale-leaseback transaction constitutes a “related party transaction” for the Company.

The Company expects to use the net proceeds from the transaction to repay its existing $6.6 million promissory note, which accrues interest at a rate of 12% per annum. The lease has an initial term of 10 years, with an option to renew for an additional 10 years. Annual rent will be $624,000 during the first year, representing 9.45% of the $6.6 million purchase price, and will increase by 2% annually. The lease will allow the Company to continue using the Durango facility as its corporate headquarters and production and warehouse facility.

“We are focused on making thoughtful financial decisions that strengthen Rocky Mountain Chocolate Factory and create a more sustainable foundation for the business,” said Mel Keating, Chairman of the Board of Directors of Rocky Mountain Chocolate Factory. “This transaction allows us to significantly reduce our existing debt while securing our continued operations at the Durango facility under a long-term lease.”

The transaction was reviewed and approved by the Company’s Audit Committee and the disinterested members of the Board of Directors, with Mr. Harper recusing himself from the review process. The purchase price was supported by an independent appraisal of the property.

About Rocky Mountain Chocolate Factory, Inc.
Rocky Mountain Chocolate Factory, Inc. is a leading franchisor, manufacturer and retailer of premium chocolates and other confectionery products. As America’s Chocolatier^® since 1981, the Company produces an extensive assortment of premium chocolates, gourmet caramel apples and other handcrafted confections. Headquartered in Durango, Colorado, Rocky Mountain Chocolate Factory is ranked among Entrepreneur’s Franchise 500^® for 2026. Together with its franchisees and licensees, the Company operates approximately 250 Rocky Mountain Chocolate Factory locations across the United States and internationally. The Company’s common stock is listed on the Nasdaq Global Market under the symbol “RMCF.”

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s anticipated use of proceeds and repayment of the promissory note, expected benefits of the transaction, anticipated interest expense savings, financial position, operating performance, strategic priorities and future growth. These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, the Company’s financial condition and operating results, and other risks described in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update any forward-looking statements except as required by applicable law.

Investor Contact
Sean Mansouri, CFA
Elevate IR
(720) 330-2829
RMCF@elevate-ir.com

Media Contact
Raymond Barrett
Director of Marketing
(305) 801-5641
rbarrett@rmcf.net

LIBERTY LAKE, Wash., Oct. 06, 2026 (GLOBE NEWSWIRE) — Itron, Inc. (NASDAQ: ITRI), which is innovating new ways for utilities and cities to manage energy and water, announced today that it will release financial results for the quarter ended Sept. 30, 2026 on Tuesday, Oct. 27, 2026 at 8:30 a.m. EDT. Itron management will host a conference call at 10:00 a.m. EDT to discuss the results.

Interested parties may listen to the conference call on a live webcast. The webcast, along with a supplemental presentation, may be accessed from the company’s website at Itron Investor Events & Presentations. Participants should access the webcast 10 minutes prior to the start of the call to install and test any necessary audio software. Participants can also pre-register for the webcast at any time using the link above.

A webcast replay of the conference call may be accessed on the company’s website at Itron Investor Events & Presentations.

About Itron

Itron is transforming how the world manages energy, water and city services. Our trusted intelligent infrastructure solutions help utilities and cities improve efficiency, build resilience and deliver safe, reliable and affordable service. With edge intelligence, we connect people, data insights and devices so communities can better manage the essential resources they rely on to live and thrive. Join us as we create a more resourceful world: www.itron.com.

Itron® and the Itron Logo are registered trademarks of Itron, Inc. in the United States and other countries and regions. All third-party trademarks are property of their respective owners, and any usage herein does not suggest or imply any relationship between Itron and the third party unless expressly stated.

For additional information, contact:

Itron, Inc.

Paul Vincent
Vice President, Investor Relations
512-560-1172

Stephanie Tarlton, CFA
Principal, Investor Relations
(512) 676-8365
investors@itron.com

Itron, Inc.

• LinkedIn: www.linkedin.com/company/itroninc
• X: https://x.com/ItronInc
• Newsroom: https://www.itron.com/newsroom
• Blog: https://blogs.itron.com

— Company to evaluate strategic alternatives to maximize stockholder value —

— Caribou plans to discontinue vispa-cel and CB-011 allogeneic CAR-T cell therapy programs —

— Cash, cash equivalents, and marketable securities of $113.8 million as of June 30, 2026 —

BERKELEY, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it is exploring strategic alternatives to maximize stockholder value and plans to discontinue further development activities for its two allogeneic CAR-T cell therapy programs, vispa-cel for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin lymphoma and CB-011 for the treatment of r/r multiple myeloma. In line with this decision, Caribou will implement workforce and cost reductions.

“This is an extraordinarily difficult decision, particularly because it is in no way a reflection of our belief that vispa-cel and CB-011 have the potential to benefit patients. Vispa-cel is pivotal trial-ready, with FDA alignment already reached on the phase 3 clinical trial design. We believe both programs have demonstrated the potential for allogeneic CAR-T cell therapies to deliver deep and durable responses, while meaningfully expanding access for patients who urgently need treatment options,” said Rachel Haurwitz, PhD, president and CEO of Caribou. “Unfortunately, despite the progress we’ve made, the current financing environment for allogeneic CAR-T cell therapies has made it increasingly challenging to secure the capital necessary to responsibly advance these programs. As a result, we’ve made the difficult decision to evaluate strategic alternatives and plan to discontinue further development of our allogeneic CAR-T cell therapy programs. We’re deeply grateful to the patients and families who placed their trust in us, the physicians and site teams who partnered with us, and every member of the Caribou team whose skill and commitment brought these programs this far and advanced the field of cell therapy.”

Caribou’s Board of Directors approved initiating a process to evaluate strategic alternatives, including, but not limited to, a merger, acquisition, business combination, or other strategic transactions involving Caribou and/or its assets. Wedbush Securities Inc. has been engaged as the company’s exclusive financial advisor to assist in the strategic evaluation process. Caribou has not set a timeline for the completion of review of strategic alternatives and does not intend to provide further updates unless and until the Board of Directors has approved a course of action, the review process is concluded, or other disclosure is otherwise determined to be appropriate. In conjunction with this announcement, Caribou plans to discontinue further clinical development activities and implement a substantial reduction in workforce, which is expected to be mostly complete in the fourth quarter of 2026.

As of June 30, 2026, Caribou had $113.8 million in cash, cash equivalents, and marketable securities.

About vispacabtagene regedleucel
Vispacabtagene regedleucel (vispa-cel; formerly known as CB-010) is an allogeneic anti-CD19 CAR-T cell therapy evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). To Caribou’s knowledge, vispa-cel is the first allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, a genome-editing strategy designed to enhance CAR-T cell activity by limiting premature CAR-T cell exhaustion. Vispa-cel is pivotal trial-ready, with FDA alignment already reached on the phase 3 clinical trial design. To Caribou’s knowledge, vispa-cel is the first allogeneic CAR-T cell therapy to demonstrate safety, efficacy, and durability on par with autologous CAR-T cell therapies. The FDA granted vispa-cel Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations for B-NHL.

About CB-011
CB-011 is an allogeneic anti-BCMA CAR-T cell therapy evaluated in patients with relapsed or refractory multiple myeloma (r/r MM). To Caribou’s knowledge, CB-011 is the first allogeneic CAR-T cell therapy in the clinic that is engineered to enable activity through an immune cloaking strategy with a B2M knockout and insertion of a B2M–HLA-E-peptide fusion protein to blunt immune-mediated rejection. Clinical data from the CB-011 CaMMouflage phase 1 trial has demonstrated the potential for deep, durable responses in patients with r/r MM. The FDA granted CB-011 RMAT, Fast Track, and Orphan Drug designations for r/r MM.

About Caribou Biosciences, Inc.
Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Caribou’s chRDNA genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. For more information, please visit www.cariboubio.com. 

Forward-looking statements and important information
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” or “continue,” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, any statements regarding Caribou’s plans to explore opportunities to maximize stockholder value, ability to enter into any agreements or transactions in connection with potential strategic transactions, or if entered into, that any such agreements or transactions will be successful or on attractive terms; Caribou’s plans for cost reductions; and the sufficiency of its estimated cash, cash equivalents, and marketable securities. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include, without limitation, risks associated with Caribou’s decision to initiate the strategic review process, including identifying and executing one or more transactions that maximize stockholder value; discontinue clinical trials and further development of its allogeneic CAR-T cell therapy programs; implement a restructuring and workforce reduction; as well as other more general risks associated with obtaining, maintaining or protecting intellectual property rights related to its product candidates and managing risks associated therewith; and managing expenses; among others; as well as other risk factors described from time to time in Caribou’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent SEC filings. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, Caribou undertakes no obligation to update publicly any forward-looking statements for any reason.

Caribou Biosciences, Inc. contact:
Peggy Vorwald, PhD
investor.relations@cariboubio.com 
media@cariboubio.com 

SPOKANE, Wash., Oct. 06, 2026 (GLOBE NEWSWIRE) — Avista Corp. (NYSE: AVA) will hold its quarterly conference call and webcast to discuss third quarter 2026 results on Wednesday, Nov. 4, 2026, at 10:30 a.m. Eastern Daylight Time. A news release with third quarter 2026 earnings information will be issued at 7:05 a.m. Eastern Daylight Time on Nov. 4, 2026.

This call can be accessed on Avista’s website at investor.avistacorp.com. You must pre-register for the call via the Presentations and Events link at Avista’s website (investor.avistacorp.com/events-and-presentations) to access the call-in details for the webcast. A replay of the webcast will be available for one year on the Avista Corp. website at investor.avistacorp.com.

Avista Corp. is an energy company involved in the production, transmission and distribution of energy as well as other energy-related businesses. Avista Utilities is the operating division that provides electric service to 429,000 customers and natural gas to 386,000 customers. Its service territory covers 34,000 square miles in eastern Washington, northern Idaho and parts of southern and eastern Oregon, with a population of 1.5 million. Alaska Energy and Resources Company is an Avista subsidiary that provides retail electric service to 18,000 customers in the city and borough of Juneau, Alaska, through its subsidiary Alaska Electric Light and Power Company. Avista stock is traded under the ticker symbol “AVA.”  For more information about Avista, please visit avistacorp.com.

Avista Corp. and the Avista Corp. logo are trademarks of Avista Corporation.

To unsubscribe from Avista’s news release distribution, send reply message to dalila.sheehan@avistacorp.com

Contact:
Media:		Avista 24/7 Media Access (509) 495-4174
		Lena Funston (509) 495-8090, lena.funston@avistacorp.com
Investors:		Stacey Walters (509) 495-2046, stacey.walters@avistacorp.com

HOLLISTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced the creation of its Scientific Advisory Board (SAB) to guide the Company’s ongoing research, development, and new product roadmaps. The SAB will meet quarterly and consists of five members, Harvard Bioscience President and CEO John Duke and four experienced industry leaders.

“The formation of our Scientific Advisory Board marks an exciting chapter for Harvard Bioscience,” said John Duke, President and CEO of Harvard Bioscience. “It brings together distinguished industry leaders to influence our R&D and new product roadmaps. The combined expertise in drug discovery, translational medicine, and launching new products will be instrumental in maximizing value for our customers and shareholders.”

The newly appointed members of the Harvard Bioscience Scientific Advisory Board include:

John Duke | President, CEO & Board Member, Harvard Bioscience

• John Duke has served as President, CEO, of Harvard Bioscience since 2025. Prior to Harvard Bioscience, he was CEO at Plastic Molding Technology, and spent 25 years at Corning Incorporated, including 10 years in Corning Life Sciences.

Dr. Ryan Conder | Director, Epithelial & Organoid Systems at STEMCELL Technologies

• Dr. Ryan Conder possesses extensive knowledge and experience with molecular biology, biochemistry, biotechnology, and drug discovery, as well as organoid systems. In addition to his work at STEMCELL Technologies, Dr. Conder currently serves as an adjunct professor at Simon Fraser University in the Department of Molecular Biology and Biochemistry.

Dr. Aaron Goldman | Director, Drug Resistance Group at Harvard Medical School

• Dr. Aaron Goldman is the founder and Director of the Drug Resistance Group at Brigham and Women’s Hospital, with nearly 20 years of experience in medical pharmacology, translational medicine, and oncology research. Dr. Goldman currently serves as an Operating Partner at BroadOak Capital Partners and an EIR at Memorial Sloan Kettering Cancer Center, and holds appointments at Dana-Farber Cancer Institute, Harvard Medical School, and Mass General Brigham.

Dr. Keith Olson | CEO, Ananda Devices

• Currently serving as the CEO of Ananda Devices, Dr. Keith Olson is a veteran life sciences executive with over three decades of leadership experience spanning drug discovery tools, new product development, sales and marketing. Prior to his role at Ananda, Dr. Olson held roles at FujiFilm Cellular Dynamics and Life Technologies.

Eric Richman | Board Member, LabConnect & SafeHeal

• Eric Richman is a seasoned board member and venture capitalist in the life sciences space, with over 25 years of experience as an executive including numerous CEO roles. Mr. Richman currently sits on the board of directors of LabConnect, SafeHeal, Polarity Bio, MicroHealth Digital, and Tempo Therapeutics. He has previously held board roles with Adma Biologics, Gain Therapeutics, F2G, Tyrogenex, and others.

About Harvard Bioscience 
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

For more information, please visit our website at www.harvardbioscience.com.

Forward-Looking Statements
This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend,” “believe” and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, information concerning expected future financial and operational performance including revenues, adjusted gross margin, adjusted EBITDA, gross margin, cash and debt position, balance sheet, growth, adoption and the introduction of new products, the strength of the Company’s market position, business model and anticipated macroeconomic conditions. Forward-looking statements do not guarantee future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company’s control. Risks and other factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include those described in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K, as well as in the Company’s other filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company’s expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available.

Company Contact:
Mark Frost
Chief Financial Officer
(508) 893-3120
investors@harvardbioscience.com

MARYSVILLE, Ohio, Oct. 06, 2026 (GLOBE NEWSWIRE) — The Scotts Miracle-Gro Company (NYSE: SMG), home to North America’s leading consumer lawn and garden brands, today announced the naming of Prathima Hegde to senior vice president and chief information officer.

In this new role, Hegde will lead enterprise IT with a focus on driving technology modernization, operational excellence, AI integration and digital capabilities to advance the SMG multi-year growth strategy and the evolution into a consumer lifestyle company. She also will support the implementation of SAP S/4HANA. Hegde reports to President and CEO Nate Baxter as a key member of the leadership team.

“The modernization of our enterprise systems will enhance our ability to exceed consumer expectations, complementing our high-performing products with seamless digital experiences and expert guidance to serve as the trusted partner for bringing their living spaces to life,” Baxter said. “Our technology upgrades will also directly power each of our SMG 2.0 building blocks by enabling product innovation, omnichannel and retail expansion, category growth and operational efficiencies.

“Prathima’s experience is directly relevant to where we are headed. She brings exceptional expertise in leading complex digital transformations and aligning technology with business outcomes. She will play a vital role in modernizing our technology core, enhancing productivity through automation and AI, and further strengthening ScottsMiracle-Gro for sustainable growth.”

Hegde has more than two decades of enterprise technology leadership across consumer packaged goods, manufacturing, healthcare and education. Most recently, as CIO of Del Monte Foods, she spearheaded enterprise IT strategy, cloud modernization, data analytics and AI initiatives. Previously, as head of corporate applications at Tropicana Brands Group, she led the technology spinoff from PepsiCo, building modern digital platforms. She has also served in senior IT roles at Adtalem Global Education and Abbott Laboratories. Hegde holds an MBA in strategy and finance from the University of Chicago Booth School of Business and a Bachelor of Science in microbiology from Osmania University.

SMG 2.0 Growth Strategy

The Company previously announced its multi-year SMG 2.0 strategy for sustainable growth and long-term shareholder value. Its building blocks include:

• Portfolio optimization and innovation to drive premium growth.
• Omnichannel and retail expansion to engage broader consumer groups.
• Category and market expansion to grow the Company’s addressable market.
• Technology-driven operational excellence with a focus on expanding margins via targeted AI, automation and supply chain efficiencies.

About ScottsMiracle-Gro
With approximately $3.3 billion in sales, the Company is the leading marketer of branded consumer lawn and garden products in North America. The Company’s brands are among the most recognized in the industry. The Company’s Scotts®, Miracle-Gro®, Ortho® and Tomcat® brands are market-leading in their categories. For additional information, visit us at www.scottsmiraclegro.com

For investor inquiries:
Brad Chelton
Vice President
Treasury, Tax and Investor Relations
brad.chelton@scotts.com
(937) 309-2503

For media inquiries:
Tom Matthews
Chief Communications Officer
tom.matthews@scotts.com
(937) 844-3864

SAN DIEGO, Oct. 06, 2026 (GLOBE NEWSWIRE) — Encore Capital Group, Inc. (Nasdaq:ECPG), an international specialty finance company, announced today that it will release its financial results for the third quarter 2026 on Wednesday, November 4, 2026, after the market closes. The Company will also host a conference call and slide presentation the same day at 2:00 p.m. Pacific / 5:00 p.m. Eastern time with Ashish Masih, President and Chief Executive Officer, Tomas Hernanz, Executive Vice President and Chief Financial Officer, and Bruce Thomas, Vice President, Global Investor Relations, presenting and discussing the reported results.

Members of the public are invited to access the live webcast via the Internet by logging in on the Investor Relations page of Encore’s website at www.encorecapital.com. To access the live conference call by telephone, please pre-register using this link. Registrants will receive confirmation with dial-in details.

For those who cannot listen to the live broadcast, a replay of the webcast will be available on the Company’s website shortly after the call concludes.

About Encore Capital Group, Inc.

Encore Capital Group is an international specialty finance company that provides debt recovery solutions and other related services for consumers across a broad range of financial assets. Through its subsidiaries around the globe, Encore purchases portfolios of consumer receivables from major banks, credit unions, and utility providers.

Encore partners with individuals as they repay their debt obligations, helping them on the road to financial recovery and ultimately improving their economic well-being. Encore is the first and only company of its kind to operate with a Consumer Bill of Rights that provides industry-leading commitments to consumers. Headquartered in San Diego, Encore is a publicly traded NASDAQ Global Select company (ticker symbol: ECPG) and a component stock of the Russell 2000, the S&P Small Cap 600 and the Wilshire 4500. More information about the company can be found at www.encorecapital.com.

Contact:
Bruce Thomas
Encore Capital Group, Inc.
bruce.thomas@encorecapital.com

SOURCE: Encore Capital Group, Inc.